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We investigated the prevalence of human papillomavirus (HPV) infection and the distribution of high-risk HPV gen-
otypes among 2,308 high-risk Korean women to predict how much the current prophylactic HPV vaccines might
affect the prevention of cervical cancer in Korea. HPV DNA was detected in 939 women (40.7%) but only one-third
of women were positive for HPV-16 and/or HPV-18, the genotypes used for developing the HPV vaccines. Thus, the
development of area-specific HPV vaccines based on dominant HPV genotypes in our country is needed for pre-
venting HPV infection and the development of premalignant lesions in the cervix of Korean women.
Findings
Infection with certain types of human papillomavirus
(HPV) is recognized as a causal and necessary factor for
developing cervical cancer [1,2], which is the fourth of
the most common cancer in South Korean women [3].
More than 140 different HPV genotypes have been char-
acterized and approximately5 0o ft h e s eg e n o t y p e sa r e
known to infect the genital tract and be oncogenic or
high-risk (HR) types (HPV-16, -18, -31, -33, -35, -39,
-45, -51, -52, -56, -58, -59, -66 and -68). HR genotypes
are significantly associated with progression to invasive
cervical cancer [2,4]. Therefore, assessment of the HPV
genotypic spectrum among sexually active women is
important for predicting public health problems such as
the risks of developing cervical intraepithelial neoplasia
and cervical cancer [5,6].
HPV-16, the most common HR type, is detected in 50
- 60% of high-grade squamous intraepithelial lesions and
invasive cervical cancers and HPV-18 is followed by an
i n c i d e n c eo f1 0-2 0 %[ 4 , 7 ] .T h u s ,H P V - 1 6a n d- 1 8a r e
considered as the types responsible for causing most
cervical cancers in many countries [4,7]. Clinical trials
have reported that these vaccines can protect many
uninfected women from developing precancerous cervi-
cal lesions caused by HPV-16 and -18 [8,9]. In spite of
their high effectiveness to reduce the incidence of cervi-
cal cancer, the usefulness of these vaccines is still being
debated because of the differences in the geographical
distribution of HPV genotypes [10].
Vaccines against HPV-16 and -18 have been devel-
oped to help the prevention of cervical cancer and the
use of Merck’s Gardasil (the quadrivalent vaccine for
HPV-6, -11, -16 and -18) and GSK’s Cervarix (the biva-
lent vaccine for HPV-16 and -18) have been licensed by
the Korea Food and Drug Administration. Population-
based study for the distribution of HPV genotype is
needed to predict how much these vaccines might influ-
ence to the prevention of cervical cancer.
In the present study, the prevalence and distribution
of HPV genotypes among high-risk women, which are
called as commercial sex workers (CSWs) by other
countries, were examined to predict whether the devel-
oped HPV vaccines are sufficient for preventing HPV
infection and the development of premalignant lesions
of the cervix in South Korea.
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sexually transmitted infection testing in public health
centers in four different regions (Seoul, Busan, Gwangju
and Jeollanamdo) was enrolled in this study. Specimens
were collected with a cytobrush for HPV testing, placed
in viral transport medium (Cellmatics Viral Transport
Pack, BD Diagnostics, Franklin Lakes, NJ, USA) and
stored at 4°C until the use for experiment. Genomic
DNA was extracted from cervical swabs by using an
AccuPrep Genomic DNA Extraction Kit (Bioneer Co.,
Seoul, South Korea) according to the manufacturer’s
instructions. Purified DNA was used to detect HPV
DNA and to determine the genotypes by using a HPV
DNA Chip (Biocore Co. Ltd., Seoul, South Korea). 939
out of 2,308 specimens were HPV positive and HPV
genotypes were typed using the HPV DNA Chip with
32 type-specific probes (HR types: HPV-16, -18, -26,
-31, -33, -35, -39, -45, -51, -52, -53, -56, -58, -59, -66,
-68 and -69; low-risk [LR] types: HPV-6, -11, -32, -34,
-40, -42, -43, -44, -54, -55, -57, -61, -62, -70 and -73).
The overall prevalence of HPV infection in these high-
risk women was 40.7%. HPV genotypes among 939
HPV-infected women were detected in 431 (45.9%) for
HR types and 147 (15.7%) for LR types, respectively. 147
(15.7%) women were infected with both genotypes. HPV
prevalence was decreased with age and the highest HPV
prevalence was observed in women under the age of 24
years old (Figure 1). The predominant HPV genotypes
in this study were HPV-16 (23.0%), HPV-58 (9.8%), and
HPV-18 (8.7%) (Figure 2). The number of HPV-infected
women with HPV-16 and -18 were 107 (11.4%) and 43
(4.6%) in a single-type infection and 109 (11.6%) and 39
(4.2%) in multiple-type infections, respectively (Table 1).
The prevalence of HPV infection in female CSWs from
other countries was 57% in the Philippines [11], 39% in
Spain [12], 32% in Australia [13] and 48% in Japan [14]. In
our previous data [15], the prevalence of HPV infection in
high-risk women was 47% with the Hybrid Capture II
method (Digene Diagnostics). Although the HPV preva-
lence among CSWs differs between countries, it was much
higher than among low-risk women and men [16]. In
addition, the prevalence of HPV infection in this study
was lower than our previous study. This result may be
generated by higher sensitivity of the Hybrid Capture
assay compared to the DNA chip method and different
population examined. The higher prevalence of HPV
infection in younger women and the decreasing trend with
age has been described by many other studies [12,17]. The
inverse relation between age and HPV prevalence has
been attributed to the development of acquired HPV
immunity over time after HPV exposure [17,18].
In this study, HPV-16 and -18 were detected only
31.7% including single or multiple infections in HPV-
infected high-risk women (Table 1). The most prevalent
HPV genotype was HPV-16 and next dominant type
was the HPV-58 (Figure 2). According to Shin et al.
[16], the prevalence of HPV infection for female univer-
sity students in Busan was 15.2% and the common HPV
genotypes were HPV-51, -53, -56, -16 and -52. In CSWs
in the Philippines, HPV-52 was the most prevalent
Figure 1 The distribution of HPV prevalence by age group. Age groups were defined based on age at enrollment into the study.
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-45 and -67 [11]. Among general gynecology practices
in South Taiwan, the prevalent genotypes were HPV-16,
-52, -58, -18 and -51 [19]. These results suggest that the
predominant HPV genotypes such as HPV-58, -52 and
-51 in Asian countries as well as HPV-16 might play
some important roles in cervical carcinogenesis in these
countries.
Even if clinical trials of prophylactic vaccines targeted
for HPV-16 and -18 showed dramatically preventive
effect for HPV infection and precancerous lesions, the
cross-protection between various HPV genotypes is still
unsolved in vaccinated women [20]. These results indi-
cate that area-specific HPV vaccines should be devel-
oped for preventing HPV infection and the subsequent
development of premalignant lesions of the cervix in
Korean women.
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Figure 2 Cross-sectional overview of HPV genotypic distribution among high-risk women in South Korea. The total number of HPV-
infected cases in each genotype, including single and multi-infection, was calculated as the percentage of the total number of infectious cases
(n = 939).
Table 1 Distribution of high-risk women infected with HPV-16 and/or HPV-18 genotypes and with single or multiple
infections by age group (n = 939)
Age (years) No. of HPV-16-infected women (%) No. of HPV-18-infected women (%)
Single Multiple Single Multiple
< 20 1 (0.9) 3 (2.8) 0 (0.0) 2 (5.1)
20-24 28 (26.2) 17 (15.6) 11 (25.6) 6 (15.4)
25-29 31 (29.0) 41 (37.6) 17 (39.5) 12 (30.8)
30-34 22 (20.6) 7 (6.4) 7 (16.3) 3 (7.7)
35-39 13 (12.1) 4 (3.7) 5 (11.6) 0 (0.0)
40-44 6 (5.6) 5 (4.6) 4 (9.3) 2 (5.1)
45-49 5 (4.7) 1 (0.9) 0 (0.0) 0 (0.0)
> 49 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0)
Total 107 (11.4) 109 (11.6) 43 (4.6) 39 (4.1)
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